PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Pivot, Xavier
TI  - Adjuvant Trastuzumab for 6 versus 12 Months in Patients with Early Breast Cancer
DP  - 2012  01
TA  - MD Conference Express
PG  - 12--13
VI  - 12
IP  - 15
4099  - http://mdc.sagepub.com/content/12/15/12.short
4100  - http://mdc.sagepub.com/content/12/15/12.full
AB  - The Finland Herceptin [FinHer] trial results and concerns about cardiac toxicity with trastuzumab provided the rationale for the Trastuzumab for 6 Months or 1 Year in Treating Women with Nonmetastatic Breast Cancer That Can Be Removed by Surgery [PHARE; NCT00381901] trial. The primary objective of this noninferiority trial was to compare the effect of 6 versus 12 months of adjuvant treatment with trastuzumab on disease-free survival in patients with HER2-positive early breast cancer.